Medical/Pharmaceuticals Global News & Press Release Distribution

Gracell Biotechnologies' Abstract on GC012F, a BCMA/CD19 Dual-targeting CAR-T Cell Therapy, Accepted for Presentation at 2022 ASCO Annual Meeting

PALO ALTO, Calif. and SUZHOU, China, April 14, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, toda...

2022-04-14 20:30 3133

China Medical System (0867.HK): the Leader in Commercialization Embraces Great Industry Opportunities as Biotech Companies are Eager to Monetize Their Innovative Products

HONG KONG, April 14, 2022 /PRNewswire/ -- Recently, China Medical System ("CMS", 0867.HK) announced its annual results. After recording continuous performance growth in the difficult time of the pandemic in 2020, it once again achieved a new record high, with revenue ofRMB 8,337 million, up 20.0%...

2022-04-14 20:24 2291

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

SHANGHAI, April 14, 2022 /PRNewswire/ -- April 13, 2022, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; Stock Code: 600196.SH, 02196.HK) announced that the Novel Coronavirus (2019-nCoV) Antigen Detection Kit (Colloidal Gold) self-developed by Fosun Diagnostics Co....

2022-04-14 19:45 3619

Fosun Diagnostics Receives China NMPA Approval for Its Independently Developed Novel Coronavirus Antigen Detection Kit Amidst of The National Efforts in Pandemic Prevention and Control

Akeso Publishes Preclinical Results of PD-1/LAG-3 Bi-specific Antibody（AK129）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/LAG-3...

2022-04-14 15:39 2751

Akeso Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody（AK131）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its PD-1/CD73 ...

2022-04-14 15:05 2455

Akeso Publishes Preclinical Results of TIGIT monoclonal antibody（AK127）at the American Association for Cancer Research (AACR) 2022 Annual Meeting

HONG KONG, April 14, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ( "Akeso" ), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, announced the publication of preclinical results of its anti-TIGIT...

2022-04-14 14:54 2669

Toyobo launches major marketing initiative for Nerbridge(TM) in the U.S., setting sights on the global nerve conduit market

OSAKA, Japan, April 13, 2022 /PRNewswire/ -- Toyobo Co., Ltd. has launched a major U.S. marketing initiative for NerbridgeTM ("the product", hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held i...

2022-04-14 10:03 2191

Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr.Humphrey Gardner as Chief Medical Officer (CMO). Dr. Gardner will be responsible for leading the global product d...

2022-04-14 08:46 2391

AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

SUZHOU, China and ROCKVILLE, Md., April 13, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has presented the latest results from six...

2022-04-14 08:28 2789

InxMed FAK Inhibitor IN10018 Received Breakthrough Therapy Designation by the China National Medical Products Administration for Platinum-Resistant Ovarian Cancer

NANJING, China, April 13, 2022 /PRNewswire/ -- InxMed Co., Ltd. announced that IN0018, its focal adhesion kinase (FAK) inhibitor, had been granted with Breakthrough Therapy Designation by the China National Medical Products Administration. This designation is based on the results of a Phase Ib...

2022-04-14 08:00 2817

Happiness Development Donated Anti-epidemic Materials to Minhang District, Shanghai

NANPING, China, April 13, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"), (NASDAQ: HAPP) an emerging and diversified company engaging in the business of production and sale of nutraceutical and dietary supplements, providing e-commerce sales and marketing solu...

2022-04-13 20:00 2871

Seed Expands into Children's Health with Launch of Its First Clinically Studied Pediatric Synbiotic

PDS-08™ reflects Seed's mission to bring scientific rigor, efficacy, and novel data generation to the global category of probiotics LOS ANGELES, April 13, 2022 /PRNewswire/ -- Seed, the microbiome science company pioneering clinically and scientifically studied next-generation probiotics, today ...

2022-04-13 18:00 2209

111, Inc. Provides Urgently-needed Items and Online Services to Support Shanghai's Fight Against Covid-19 Pandemic

SHANGHAI, April 13, 2022 /PRNewswire/ -- On April, 2022, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, has set up an "Anti-Epidemic Command" at the first opportunity to coordinate its relevant departments and manpower to fully partic...

2022-04-13 17:02 2688

AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

SHANGHAI, April 12, 2022 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, today announced that DEXTENZA has been approved inMacau, China for...

2022-04-13 10:46 2835

HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative

* HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies * Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, South Korea ,April 12, 2022 /PRNewswire/ -- HanAll...

2022-04-13 08:00 2451

Bridge Biotherapeutics Presented the Preclinical Data of BBT-207 at the AACR Annual Meeting 2022

* The preclinical data supports the clinical development of BBT-207 for EGFR mutant NSCLC patients harboring C797S double mutations, as well as for those who are treatment-naïve * The company plans to submit an IND application to the US FDA in 2022 and looks forward to entering the Phase 1 st...

2022-04-13 06:00 1815

MediLink Therapeutics Receives FDA Clearance of IND Application for YL201 Antibody Drug Conjugate Product

SUZHOU, China, April 12, 2022 /PRNewswire/ -- MediLink Therapeutics announced that YL201, the first compound based on MediLink's proprietary antibody-drug conjugate (ADC) technology platform, has been cleared on its Investigational New Drug (IND) application by the U.S. Food and Drug Administrati...

2022-04-12 20:55 1412

CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the Orphan-drug Designation by the Food and Drug Administration of the United States

CHENGDU, China, April 12, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that its new drug candidate CMG901 (the "Claudin 18.2 antibody drug conjugates") for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma has been granted the Orphan-drug Designation by t...

2022-04-12 15:45 1421

/DISREGARD RELEASE: HanAll Biopharma and Daewoong Pharmaceutical/

We are advised by HanAll Biopharma and Daewoong Pharmaceutical that journalists and other readers should disregard the news release, "Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative", issued11-Apr-2022 over PR Newswire. ...

2022-04-12 15:34 2772

PharmAbcine Presents Updated Preclinical Data of Its Anti-VISTA Antibody Candidate at AACR 2022

DAEJEON, South Korea, April 11, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), aclinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company presented an updated preclinical data PMC-309, the Company's anti-VISTA ...

2022-04-11 20:00 1741